Wockhardt’s Zaynich achieves 97% efficacy in treating resistant infections

Wockhardt Limited has announced that its proprietary antibiotic combination, Zaynich® (Zidebactam/Cefepime, WCK 5222), demonstrated over 97% clinical efficacy in a pivotal study targeting carbapenem-resistant Gram-negative pathogens. Conducted across 15 leading tertiary hospitals in India, the study included patients with severe infections such as bloodstream infections (BSI), hospital-acquired bacterial pneumonia (HABP), and complicated urinary tract infections (cUTI).

Key Findings:

Advertisement

  • Overall clinical efficacy: 98% across indications, with 100% success in treating BSI, HABP, and cIAI (complicated intra-abdominal infections).
  • Pathogen eradication rates: 91% for HABP and 100% for BSI.
  • Treatment involved extensively drug-resistant (XDR) pathogens like Acinetobacter spp., Klebsiella spp., and E. coli.

The study, approved by India’s Drugs Controller General, underscores the life-saving potential of Zaynich®, especially against infections resistant to existing treatments like colistin and polymyxins.

Global Relevance: Zaynich® addresses critical antimicrobial resistance concerns identified by global health authorities, including the CDC and WHO. Wockhardt’s discovery is positioned as a breakthrough in combating multi-drug resistant “superbugs.”

About Wockhardt: A global pharmaceutical leader, Wockhardt focuses on novel antibacterial solutions, with six products granted Qualified Infectious Disease Product (QIDP) status by the US FDA. The company operates in key markets, including the US, UK, and India, with 79% of its revenues coming from international businesses.